Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

SPECIFIC PHARMA A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   6.2% 1.9% 2.0% 1.9% 1.7% 1.7% 4.8% 4.8%   Credit score (0-100)   39 71 69 69 73 71 45 45   Credit rating   BBB A A A A A BBB BBB   Credit limit (mDKK)   0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Net sales   146 128 140 123 178 211 211 211   Gross profit   25.3 27.0 32.5 26.4 34.7 48.5 0.0 0.0   EBITDA   12.6 11.6 16.6 9.6 17.4 28.9 0.0 0.0   EBIT   12.6 11.6 16.6 9.6 16.7 28.8 0.0 0.0   Pre-tax profit (PTP)   11.5 8.2 14.8 7.8 12.7 32.8 0.0 0.0   Net earnings   8.9 8.2 14.8 7.8 9.9 25.6 0.0 0.0   Pre-tax profit without non-rec. items   11.5 11.6 16.6 9.6 12.7 32.8 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0   Shareholders equity total   78.6 80.2 88.8 85.5 89.6 106 77.0 77.0   Interest-bearing liabilities   0.5 0.0 0.0 0.0 1.2 0.6 0.0 0.0   Balance sheet total (assets)   93.1 95.3 107 103 105 126 77.0 77.0   Net Debt   0.5 0.0 0.0 0.0 1.2 0.6 -77.0 -77.0     See the entire balance sheet 1.0 Volume  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Net sales   146 128 140 123 178 211 211 211   Net sales growth   0.5% -12.4% 8.9% -11.7% 44.1% 18.8% 0.0% 0.0%   Gross profit   25.3 27.0 32.5 26.4 34.7 48.5 0.0 0.0   Gross profit growth   -14.9% 6.7% 20.5% -18.9% 31.7% 39.7% -100.0% 0.0%   Employees   21 23 25 25 28 33 0 0   Employee growth %   31.3% 9.5% 8.7% 0.0% 12.0% 17.9% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   93 95 107 103 105 126 77 77   Balance sheet change%   6.6% 2.3% 12.5% -3.9% 1.8% 20.2% -39.0% 0.0%   Added value   12.6 11.6 16.6 9.6 16.7 28.9 0.0 0.0   Added value %   8.6% 9.0% 11.9% 7.8% 9.4% 13.7% 0.0% 0.0%   Investments   0 0 0 0 -0 -0 -0 0   Net sales trend   2.0 -1.0 1.0 -1.0 1.0 2.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1.0 Profitability  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A EBITDA %   8.6% 9.0% 11.9% 7.8% 9.8% 13.7% 0.0% 0.0%   EBIT %   8.6% 9.0% 11.9% 7.8% 9.4% 13.6% 0.0% 0.0%   EBIT to gross profit (%)   49.8% 43.0% 51.1% 36.4% 48.0% 59.3% 0.0% 0.0%   Net Earnings %   6.1% 6.4% 10.6% 6.3% 5.6% 12.1% 0.0% 0.0%   Profit before depreciation and extraordinary items %   6.1% 6.4% 10.6% 6.3% 6.0% 12.2% 0.0% 0.0%   Pre tax profit less extraordinaries %   7.8% 9.0% 11.9% 7.8% 7.1% 15.5% 0.0% 0.0%   ROA %   14.5% 12.3% 16.4% 9.1% 16.6% 28.5% 0.0% 0.0%   ROI %   17.4% 13.3% 16.4% 9.1% 17.8% 33.2% 0.0% 0.0%   ROE %   12.0% 10.4% 17.5% 8.9% 11.3% 26.1% 0.0% 0.0%   1.0 Solidity  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Equity ratio %   84.5% 100.0% 100.0% 100.0% 85.3% 84.2% 100.0% 100.0%   Relative indebtedness %   9.9% 0.0% 0.0% 0.0% 8.7% 9.4% 0.0% 0.0%   Relative net indebtedness %   9.9% 0.0% 0.0% 0.0% 8.7% 9.4% -36.5% -36.5%   Net int. bear. debt to EBITDA, %   3.8% 0.0% 0.0% 0.0% 6.8% 2.1% 0.0% 0.0%   Gearing %   0.6% 0.0% 0.0% 0.0% 1.3% 0.6% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   183.0% 0.0% 0.0% 0.0% 784.1% 13.4% 0.0% 0.0%   1.0 Liquidity  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Quick Ratio   5.0 0.0 0.0 0.0 5.4 5.0 0.0 0.0   Current Ratio   6.4 0.0 0.0 0.0 6.8 6.4 0.0 0.0   Cash and cash equivalent   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   1.0 Capital use efficiency  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Trade debtors turnover (days)   14.8 0.0 0.0 0.0 23.8 17.7 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 222.0 234.0 0.0 0.0   Current assets / Net sales %   63.6% 0.0% 0.0% 0.0% 59.0% 59.7% 36.5% 36.5%   Net working capital   78.6 0.0 0.0 0.0 89.4 106.2 0.0 0.0   Net working capital %   53.7% 0.0% 0.0% 0.0% 50.4% 50.3% 0.0% 0.0%   1.0 Employee efficiency  2018 2019/1 2019 2020/1 2020 2021/1 2021 2022/1 2022 2023/1 2023 2024/1 2024e N/A 2025e N/A Net sales / employee   7 6 6 5 6 6 0 0   Added value / employee   1 1 1 0 1 1 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   1 1 1 0 1 1 0 0   EBIT / employee   1 1 1 0 1 1 0 0   Net earnings / employee   0 0 1 0 0 1 0 0